Drug Trial Radar · NCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Sep 25, 2024
Primary completion
Oct 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Cybrexa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Conditions
- Platinum-resistant Ovarian Cancer
- Refractory Ovarian Carcinoma
Interventions
CBX-12Drug
CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]Time frame: Randomization to progressive disease (PD) (Up to approximately 21 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TMC Health
Tucson, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.